Browsing by Author Bafaloukos, D.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 10 to 29 of 60 < previous   next >
TitleAuthor(s)Issue date???itemlist.???
Docetaxel and gemcitabine in anthracycline-resistant advanced breast cancer: a Hellenic Cooperative Oncology Group Phase II studyFountzilas, G.; Nicolaides, C.; Bafaloukos, D.; Kalogera-Fountzila, A.; Kalofonos, H.; Samelis, G.; Aravantinos, G.; Pavlidis, N.24-Nov-2015-
Docetaxel in combination with dacarbazine in patients with advanced melanomaBafaloukos, D.; Aravantinos, G.; Fountzilas, G.; Stathopoulos, G.; Gogas, H.; Samonis, G.; Briasoulis, E.; Mylonakis, N.; Skarlos, D. V.; Kosmidis, P.24-Nov-2015-
Dose-dense adjuvant chemotherapy with epirubicin monotherapy in patients with operable breast cancer and >/=10 positive axillary lymph nodes. A feasibility studyFountzilas, G.; Nicolaides, C.; Aravantinos, G.; Skarlos, D.; Kosmidis, P.; Papakostas, P.; Stathopoulos, G. P.; Kontostolis, E.; Bafaloukos, D.; Pavlidis, N.24-Nov-2015-
Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancerFountzilas, G.; Papadimitriou, C.; Aravantinos, G.; Nicolaides, C.; Stathopoulos, G.; Bafaloukos, D.; Kalofonos, H.; Ekonomopoulos, T.; Skarlos, D.; Pavlidis, N.; Dimopoulos, A. M.24-Nov-2015-
Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancerRazis, E.; Dimopoulos, A. M.; Bafaloukos, D.; Papadimitriou, C.; Kalogera-Fountzila, A.; Kalofonos, H.; Briassoulis, E.; Samantas, E.; Keramopoulos, A.; Pavlidis, N.; Kosmidis, P.; Fountzilas, G.24-Nov-2015-
Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Papadimitriou, C.; Dafni, U.; Bafaloukos, D.; Skarlos, D.; Moulopoulos, L. A.; Razis, E.; Kalofonos, H. P.; Aravantinos, G.; Briassoulis, E.; Papakostas, P.; Abela, K.; Gogas, E.; Kosmidis, P.; Pavlidis, N.; Dimopoulos, M. A.24-Nov-2015-
Evaluation of 6 Tumor-Markers in Patients with Carcinoma of Unknown PrimaryPavlidis, N.; Kalefezra, J.; Briassoulis, E.; Skarlos, D.; Kosmidis, P.; Saferiadis, K.; Bairaktari, E.; Bafaloukos, D.; Maravegias, A.; Theoharis, D.; Fountzilas, G.24-Nov-2015-
Evaluation of six tumor markers in patients with carcinoma of unknown primaryPavlidis, N.; Kalef-Ezra, J.; Briassoulis, E.; Skarlos, D.; Kosmidis, P.; Saferiadis, K.; Bairaktari, E.; Bafaloukos, D.; Maravegias, A.; Theoharis, D.; et al.,24-Nov-2015-
Evaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyMalamou-Mitsi, V.; Gogas, H.; Dafni, U.; Bourli, A.; Fillipidis, T.; Sotiropoulou, M.; Vlachodimitropoulos, D.; Papadopoulos, S.; Tzaida, O.; Kafiri, G.; Kyriakou, V.; Markaki, S.; Papaspyrou, I.; Karagianni, E.; Pavlakis, K.; Toliou, T.; Scopa, C.; Papakostas, P.; Bafaloukos, D.; Christodoulou, C.; Fountzilas, G.24-Nov-2015-
First-line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advanced breast cancer (final report): a phase II study conducted by the Hellenic Cooperative Oncology GroupFountzilas, G.; Dimopoulos, A. M.; Papadimitriou, C.; Kalogera-Fountzila, A.; Aravantinos, G.; Bafaloukos, D.; Athanassiades, A.; Nicolaides, C.; Keramopoulos, A.; Pavlidis, N.; Kosmidis, P.; Skarlos, D.24-Nov-2015-
Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer progressing after first-line taxane-based chemotherapy: a phase II study conducted by the Hellenic Cooperative Oncology GroupNicolaides, C.; Dimopoulos, M. A.; Samantas, E.; Bafaloukos, D.; Kalofonos, C.; Fountzilas, G.; Razi, E.; Kosmidis, P.; Pavlidis, N.24-Nov-2015-
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II studySkarlos, D. V.; Kalofonos, H. P.; Fountzilas, G.; Dimopoulos, M. A.; Pavlidis, N.; Razis, E.; Economopoulos, T.; Pectasides, D.; Gogas, H.; Kosmidis, P.; Bafaloukos, D.; Klouvas, G.; Kyratzis, G.; Aravantinos, G.24-Nov-2015-
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trialPentheroudakis, G.; Kalogeras, K. T.; Wirtz, R. M.; Grimani, I.; Zografos, G.; Gogas, H.; Stropp, U.; Pectasides, D.; Skarlos, D.; Hennig, G.; Samantas, E.; Bafaloukos, D.; Papakostas, P.; Kalofonos, H. P.; Pavlidis, N.; Fountzilas, G.24-Nov-2015-
High-dose epirubicin and r-met-hu G-CSF (filgrastim) in the treatment of patients with advanced breast cancer: A Hellenic Cooperative Oncology Group studyFountzilas, G.; Skarlos, D.; Katsohis, C.; Pavlidis, N.; Giannakakis, T.; Bafaloukos, D.; Fahantidis, E.; Klouvas, G.; Beer, M.; Kosmidis, P.24-Nov-2015-
Ifosfamide plus oral etoposide salvage chemotherapy for platinum-resistant paclitaxel-pretreated ovarian cancerAravantinos, G.; Dimopoulos, M. A.; Kosmidis, P.; Bafaloukos, D.; Papadimitriou, C.; Kiamouris, C.; Pavlidis, N.; Sikiotis, K.; Papakostas, P.; Skarlos, D. V.24-Nov-2015-
Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in advanced breast cancerFountzilas, G.; Skarlos, D.; Giannakakis, T.; Athanasiadis, A.; Bafaloukos, D.; Kalogera-Fountzila, A.; Bamia, C.; Pavlidis, N.; Kosmidis, P.24-Nov-2015-
Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerationsPallis, A.; Briasoulis, E.; Linardou, H.; Papadimitriou, C.; Bafaloukos, D.; Kosmidis, P.; Murray, S.24-Nov-2015-
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 womenPentheroudakis, G.; Fountzilas, G.; Bafaloukos, D.; Koutsoukou, V.; Pectasides, D.; Skarlos, D.; Samantas, E.; Kalofonos, H. P.; Gogas, H.; Pavlidis, N.24-Nov-2015-
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome dataMauri, D.; Pentheroudakis, G.; Bafaloukos, D.; Pectasides, D.; Samantas, E.; Efstathiou, E.; Kalofonos, H. P.; Syrigos, K.; Klouvas, G.; Papakostas, P.; Kosmidis, P.; Fountzilas, G.; Pavlidis, N.24-Nov-2015-
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluationFountzilas, G.; Kourea, H. P.; Bobos, M.; Televantou, D.; Kotoula, V.; Papadimitriou, C.; Papazisis, K. T.; Timotheadou, E.; Efstratiou, I.; Koutras, A.; Pentheroudakis, G.; Christodoulou, C.; Aravantinos, G.; Miliaras, D.; Petraki, K.; Papandreou, C. N.; Papakostas, P.; Bafaloukos, D.; Repana, D.; Razis, E.; Pectasides, D.; Dimopoulos, A. M.24-Nov-2015-